1. Market Research
  2. > Neurology – Pipeline Review, H1 2013

Neurology – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 92 pages

Neurology – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Neurology - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurology, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurology. Neurology - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neurology.
- A review of the Neurology products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neurology pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neurology.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neurology pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neurology - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Neurology Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Neurology 9
Neurology Therapeutics under Development by Companies 11
Neurology Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Neurology Therapeutics - Products under Development by Companies 22
Neurology Therapeutics - Products under Investigation by Universities/Institutes 27
Companies Involved in Neurology Therapeutics Development 28
Bristol-Myers Squibb Company 28
Johnson and Johnson 29
Boehringer Ingelheim GmbH 30
F. Hoffmann-La Roche Ltd. 31
Antares Pharma, Inc. 32
Sanofi-Aventis 33
Isis Pharmaceuticals, Inc. 34
Merck and Co., Inc. 35
Ipsen S.A. 36
Reliance Life Sciences Pvt. Ltd. 37
Eisai Co., Ltd. 38
H Lundbeck A/S 39
Ildong Pharmaceutical Co., Ltd. 40
Mitsubishi Tanabe Pharma Corporation 41
UCB Group 42
Oxygen Biotherapeutics, Inc. 43
Evotec Aktiengesellschaft 44
AVANIR Pharmaceuticals 45
Lixte Biotechnology Holdings, Inc. 46
Catalyst Pharmaceutical Partners, Inc. 47
ReNeuron Group plc 48
PhytoHealth Corporation 49
Biotie Therapies Corp. 50
Allon Therapeutics Inc. 51
ThromboGenics NV 52
Stem Cell Therapeutics Corp. 53
NeuroVive Pharmaceutical AB 54
Daiichi Sankyo, Inc. 55
Asubio Pharmaceuticals, Inc. 56
D-Pharm Ltd. 57
KeyNeurotek Pharmaceuticals AG 58
Palau Pharma S.A 59
Osmotica Pharmaceutical Corp. 60
Chiome Bioscience, Inc. 61
Remedy Pharmaceuticals, Inc. 62
TetraLogic Pharmaceuticals 63
Omeros Corporation 64
SanBio, Inc. 65
Glucox Biotech 66
M's Science Corporation 67
NeuroHealing Pharmaceuticals Inc. 68
Manipal AcuNova Ltd 69
Kuhnil Pharmaceutical Co., Ltd. 70
Gaia BioPharma Limited 71
Stempeutics Research Private Limited 72
STATegics, Inc. 73
Neurology - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Neurology Therapeutics - Discontinued Products 80
Neurology Therapeutics - Dormant Products 82
Neurology - Product Development Milestones 86
Featured News and Press Releases 86
Jun 10, 2013: Supernus Receives Tentative Approval for Trokendi XR 86
Jun 05, 2013: Avanir Pharma Announces Accelerated Development Path For AVP-786 Following Successful Pre-IND Meeting With FDA 86
Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin 86
Feb 07, 2013: Avanir Pharma Announces Positive Interim Data From Pharmacokinetic Study With AVP-786 87
Feb 07, 2013: Concert Pharma Announces Milestone Achievement In Avanir Pharma Collaboration 87
Jan 14, 2013: SanBio Announces Enrollment Of Second Cohort Of Patients In Clinical Trial Of Stem Cell Therapy For Chronic Stroke 88
Dec 28, 2012: Mylan Launches Generic Dilantin Chewable Tablets 89
Dec 28, 2012: Mylan Launches Generic Dilantin Chewable Tablets 89
Dec 24, 2012: Neuren Pharma Receives FDA Approval For Phase II trial Of NNZ-2566 In Rett Syndrome 89
Dec 04, 2012: ReNeuron To Present Data On ReN001 Stem Cell Therapy At UK Stroke Forum Conference 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables

Number of Products Under Development for Neurology, H1 2013 9
Products under Development for Neurology - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Development by Companies, H1 2013 (Contd..1) 13
Number of Products under Development by Companies, H1 2013 (Contd..2) 14
Number of Products under Development by Companies, H1 2013 (Contd..3) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Development by Companies, H1 2013 (Contd..3) 25
Products under Development by Companies, H1 2013 (Contd..4) 26
Products under Investigation by Universities/Institutes, H1 2013 27
Bristol-Myers Squibb Company, H1 2013 28
Johnson and Johnson, H1 2013 29
Boehringer Ingelheim GmbH, H1 2013 30
F. Hoffmann-La Roche Ltd., H1 2013 31
Antares Pharma, Inc., H1 2013 32
Sanofi-Aventis, H1 2013 33
Isis Pharmaceuticals, Inc., H1 2013 34
Merck and Co., Inc., H1 2013 35
Ipsen S.A., H1 2013 36
Reliance Life Sciences Pvt. Ltd., H1 2013 37
Eisai Co., Ltd., H1 2013 38
H Lundbeck A/S, H1 2013 39
Ildong Pharmaceutical Co., Ltd., H1 2013 40
Mitsubishi Tanabe Pharma Corporation, H1 2013 41
UCB Group, H1 2013 42
Oxygen Biotherapeutics, Inc., H1 2013 43
Evotec Aktiengesellschaft, H1 2013 44
AVANIR Pharmaceuticals, H1 2013 45
Lixte Biotechnology Holdings, Inc., H1 2013 46
Catalyst Pharmaceutical Partners, Inc., H1 2013 47
ReNeuron Group plc, H1 2013 48
PhytoHealth Corporation, H1 2013 49
Biotie Therapies Corp., H1 2013 50
Allon Therapeutics Inc., H1 2013 51
ThromboGenics NV, H1 2013 52
Stem Cell Therapeutics Corp., H1 2013 53
NeuroVive Pharmaceutical AB, H1 2013 54
Daiichi Sankyo, Inc., H1 2013 55
Asubio Pharmaceuticals, Inc., H1 2013 56
D-Pharm Ltd., H1 2013 57
KeyNeurotek Pharmaceuticals AG, H1 2013 58
Palau Pharma S.A, H1 2013 59
Osmotica Pharmaceutical Corp., H1 2013 60
Chiome Bioscience, Inc., H1 2013 61
Remedy Pharmaceuticals, Inc., H1 2013 62
TetraLogic Pharmaceuticals, H1 2013 63
Omeros Corporation, H1 2013 64
Glucox Biotech, H1 2013 66
M's Science Corporation, H1 2013 67
NeuroHealing Pharmaceuticals Inc., H1 2013 68
Manipal AcuNova Ltd, H1 2013 69
Kuhnil Pharmaceutical Co., Ltd., H1 2013 70
Gaia BioPharma Limited, H1 2013 71
STATegics, Inc., H1 2013 73
Assessment by Monotherapy Products, H1 2013 74
Assessment by Stage and Route of Administration, H1 2013 76
Assessment by Stage and Molecule Type, H1 2013 79
Neurology Therapeutics - Discontinued Products 80
Neurology Therapeutics - Discontinued Products (Contd..1) 81
Neurology Therapeutics - Dormant Products 82
Neurology Therapeutics - Dormant Products (Contd..1) 83
Neurology Therapeutics - Dormant Products (Contd..2) 84
Neurology Therapeutics - Dormant Products (Contd..3) 85

List of Figures

Number of Products under Development for Neurology, H1 2013 9
Products under Development for Neurology - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 74
Assessment by Route of Administration, H1 2013 75
Assessment by Stage and Route of Administration, H1 2013 76
Assessment by Molecule Type, H1 2013 77
Assessment by Stage and Molecule Type, H1 2013 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.